JP2020514301A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514301A5
JP2020514301A5 JP2019537110A JP2019537110A JP2020514301A5 JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5 JP 2019537110 A JP2019537110 A JP 2019537110A JP 2019537110 A JP2019537110 A JP 2019537110A JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5
Authority
JP
Japan
Prior art keywords
domain
domain monomer
monomer
polypeptide
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019537110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012689 external-priority patent/WO2018129397A1/en
Publication of JP2020514301A publication Critical patent/JP2020514301A/ja
Publication of JP2020514301A5 publication Critical patent/JP2020514301A5/ja
Pending legal-status Critical Current

Links

JP2019537110A 2017-01-06 2018-01-05 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Pending JP2020514301A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443523P 2017-01-06 2017-01-06
US62/443,523 2017-01-06
PCT/US2018/012689 WO2018129397A1 (en) 2017-01-06 2018-01-05 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (2)

Publication Number Publication Date
JP2020514301A JP2020514301A (ja) 2020-05-21
JP2020514301A5 true JP2020514301A5 (cg-RX-API-DMAC7.html) 2021-02-18

Family

ID=62791385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019537110A Pending JP2020514301A (ja) 2017-01-06 2018-01-05 改変されたFc抗原結合ドメイン構築体に関する組成物および方法

Country Status (7)

Country Link
US (1) US20200040084A1 (cg-RX-API-DMAC7.html)
EP (1) EP3565595A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020514301A (cg-RX-API-DMAC7.html)
AU (1) AU2018205272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3049426A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019124709A (cg-RX-API-DMAC7.html)
WO (1) WO2018129397A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
US20210317227A1 (en) * 2018-07-11 2021-10-14 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CN113164591A (zh) * 2018-07-11 2021-07-23 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021000288A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
CA3106254A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Cd137およびgpc3に特異的な新規融合タンパク質
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
EP4031166A1 (en) * 2019-09-18 2022-07-27 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
KR102963172B1 (ko) * 2021-10-22 2026-05-18 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
WO2024219897A1 (ko) 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
TW202504932A (zh) 2023-04-21 2025-02-01 南韓商百歲生命科學股份有限公司 包含兩個fc區域之抗原結合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
WO2008137382A1 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
WO2012116926A1 (en) * 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
PH12014500220A1 (en) * 2011-07-27 2019-03-22 Glaxo Group Ltd Anti-vegf single variable domains fused to fc domains
SG11201506451UA (en) * 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs

Similar Documents

Publication Publication Date Title
JP2020508655A5 (cg-RX-API-DMAC7.html)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2018046872A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2016505556A5 (cg-RX-API-DMAC7.html)
JP2020022482A5 (cg-RX-API-DMAC7.html)
ES2533963T3 (es) Composiciones farmacéuticas dirigidas a receptores Erb-B1
JP2021532085A5 (cg-RX-API-DMAC7.html)
JP2022545647A5 (cg-RX-API-DMAC7.html)
JP2022507487A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2023507729A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
IL299221A (en) Cd3 binding antibodies
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
RU2013141956A (ru) Антитело против ксф-1r
JP2018507188A5 (cg-RX-API-DMAC7.html)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2010523592A5 (cg-RX-API-DMAC7.html)
RU2017129236A (ru) Мультивалентные молекулы, содержащие dr5-связывающие домены
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
JP2024512135A5 (cg-RX-API-DMAC7.html)
JP2019528694A5 (cg-RX-API-DMAC7.html)
JP2011526249A5 (cg-RX-API-DMAC7.html)